Switch theme
Sign up to access all valuation multiples
Wockhardt Ltd is a drug manufacturing company focusing on pharmaceutical and biotechnology products. The company conducts research in the fields of pharmaceuticals and biotechnology while also operating its chain of Super Specialty Hospitals. The vast majority of the company's revenue is generated in Europe. The company also operates in the USA, Japan, Russia, and Rest of the world.
1999
2.4K+
Last FY Revenue $353M
Last FY EBITDA $53.3M
$2.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Wockhardt achieved revenue of $353M and an EBITDA of $53.3M.
Wockhardt expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wockhardt valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $353M | XXX | XXX | XXX |
| Gross Profit | XXX | $220M | XXX | XXX | XXX |
| Gross Margin | XXX | 62% | XXX | XXX | XXX |
| EBITDA | XXX | $53.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 15% | XXX | XXX | XXX |
| EBIT | XXX | $21.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | 6% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.5M | XXX | XXX | XXX |
| Net Margin | XXX | -2% | XXX | XXX | XXX |
| Net Debt | XXX | $205M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Wockhardt's stock price is INR 1464 (or $17).
Wockhardt has current market cap of INR 238B (or $2.8B), and EV of INR 252B (or $2.9B).
See Wockhardt trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.9B | $2.8B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Wockhardt has market cap of $2.8B and EV of $2.9B.
Wockhardt's trades at 8.5x EV/Revenue multiple, and 69.0x EV/EBITDA.
Equity research analysts estimate Wockhardt's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wockhardt's P/E ratio is not available.
See valuation multiples for Wockhardt and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV (current) | $2.9B | XXX | $2.9B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 69.0x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 197.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -157.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -86.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWockhardt's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Wockhardt's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Wockhardt's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Wockhardt and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 12% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wockhardt acquired XXX companies to date.
Last acquisition by Wockhardt was XXXXXXXX, XXXXX XXXXX XXXXXX . Wockhardt acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Wockhardt founded? | Wockhardt was founded in 1999. |
| Where is Wockhardt headquartered? | Wockhardt is headquartered in India. |
| How many employees does Wockhardt have? | As of today, Wockhardt has 2.4K+ employees. |
| Is Wockhardt publicy listed? | Yes, Wockhardt is a public company listed on BOM. |
| What is the stock symbol of Wockhardt? | Wockhardt trades under 532300 ticker. |
| When did Wockhardt go public? | Wockhardt went public in 2000. |
| Who are competitors of Wockhardt? | Similar companies to Wockhardt include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Wockhardt? | Wockhardt's current market cap is $2.8B |
| Is Wockhardt profitable? | Yes, Wockhardt is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
